Praxis Submits Two Key Drug Applications to FDA

Praxis Files Two NDAs with FDA on February 19

Praxis Precision Medicines announced on February 19, 2026, that it submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration. The first application is for ulixacaltamide, a drug candidate designed to treat essential tremor (ET), a common movement disorder. The second is for relutrigine, which targets rare and severe SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).

This dual submission marks a pivotal moment for the company, advancing two of its key assets from clinical development to formal regulatory review. The filing initiates a process where the FDA will evaluate the safety and efficacy data from Praxis's clinical trials to determine if the treatments can be approved for marketing in the United States.

Regulatory Milestone Signals Future Revenue Potential

For a clinical-stage biotechnology firm like Praxis, an NDA submission is a major de-risking event and a key value inflection point. It represents the culmination of extensive research, development, and capital investment. Investor focus now shifts to the FDA's review process, which will determine the commercial fate of both drug candidates.

A successful review and subsequent approval would transform Praxis from a development company into a commercial one, opening up substantial revenue streams from two distinct patient populations. The potential approval for ulixacaltamide in the larger essential tremor market, coupled with relutrigine for rare seizure disorders, positions the company to address significant unmet medical needs and could serve as a powerful catalyst for its stock price.